Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data. Asian Pac J Cancer Prev 2019 Apr 29;20(4):987-990
Date
04/30/2019Pubmed ID
31030464Pubmed Central ID
PMC6948904DOI
10.31557/APJCP.2019.20.4.987Scopus ID
2-s2.0-85065403037 (requires institutional sign-in at Scopus site) 1 CitationAbstract
We present the first-ever autologous stem cell transplantation (ASCT) outcome data from a secondary-care healthcare facility. Albeit exact details of patient and disease characteristics and co-morbidity scores for all patients are not available, the engraftment and survival data is very similar to those published from large tertiary-care cancer centres, both regionally and internationally. Transplant Related Mortality (TRM) of 3.1% is within the expected range and includes a patient who died of acute drug reaction (ADR) during conditioning chemotherapy, prior to the ASCT. Furthermore, cyclophosphamide mobilization chemotherapy is given in the outpatient setting. This study is important in terms of healthcare resource optimization as well as patients’ convenience and highlights that ASCT can be performed in a safe and effective manner with comparable survival rates even at a DGH, provided the centre stays abreast with the recent developments and can offer its patients with standard of care treatment of the era.
Author List
Abid MB, Mughal M, Babbra R, Abid MA, Blesing N, Anwer SMESH terms used to index this publication - Major topics in bold
AdultAged
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hospitals, Low-Volume
Humans
Lymphoma
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
Transplantation, Autologous
